Parexel CEO sells $2.4M in stock

Parexel CEO sells $2.4M in stock
Parexel CEO Josef Von Rickenbach unloaded 50,000 shares of stock last Friday. 

The stock was worth $2.485M, according to SEC documents​. Von Rickenbach still owns about $30M in stock, according to news reports​.

The sell-off comes as Parexel recently exceeded expectations​ with its second quarter results.

Analysts at Barclays raised their price target on Parexel shares from $48.00 to $52.00 in a research note from last week, while analysts at ISI Group upgraded shares of the company’s stock from a “buy​” rating to a “strong-buy​” rating in a research note to investors on Wednesday, January 22nd.

And analysts at Thomson Reuters/Verus downgraded shares of Parexel. One research analyst has rated the stock with a sell rating, seven have given it a hold rating, five have offered a buy rating and two have said the stock deserves a strong buy rating, according to reports. 

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Webinars

Headlines